Caseware UK (AP4) 2024.0.164 2024.0.164 2025-05-012025-05-01The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.No description of principal activityfalse1false2023-09-270falsetrue 15169544 2023-09-26 15169544 2023-09-27 2024-09-30 15169544 2022-09-27 2023-09-26 15169544 2024-09-30 15169544 c:Director1 2023-09-27 2024-09-30 15169544 d:CurrentFinancialInstruments 2024-09-30 15169544 d:CurrentFinancialInstruments d:WithinOneYear 2024-09-30 15169544 d:ShareCapital 2024-09-30 15169544 d:SharePremium 2023-09-27 2024-09-30 15169544 d:SharePremium 2024-09-30 15169544 d:RetainedEarningsAccumulatedLosses 2023-09-27 2024-09-30 15169544 d:RetainedEarningsAccumulatedLosses 2024-09-30 15169544 c:OrdinaryShareClass1 2023-09-27 2024-09-30 15169544 c:OrdinaryShareClass2 2023-09-27 2024-09-30 15169544 c:OrdinaryShareClass2 2024-09-30 15169544 c:OrdinaryShareClass3 2023-09-27 2024-09-30 15169544 c:OrdinaryShareClass3 2024-09-30 15169544 c:OrdinaryShareClass4 2023-09-27 2024-09-30 15169544 c:OrdinaryShareClass4 2024-09-30 15169544 c:FRS102 2023-09-27 2024-09-30 15169544 c:AuditExemptWithAccountantsReport 2023-09-27 2024-09-30 15169544 c:FullAccounts 2023-09-27 2024-09-30 15169544 c:PrivateLimitedCompanyLtd 2023-09-27 2024-09-30 15169544 e:PoundSterling 2023-09-27 2024-09-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 15169544










Ateda Therapeutics Limited








Unaudited

Financial statements

Information for filing with the registrar

For the Period Ended 30 September 2024

 
Ateda Therapeutics Limited
 
  
Chartered Accountants' Report to the Director on the preparation of the Unaudited Statutory Financial Statements of Ateda Therapeutics Limited for the Period Ended 30 September 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Ateda Therapeutics Limited for the period ended 30 September 2024 which comprise  the Balance Sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW)we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com /regulation.

This report is made solely to the director of Ateda Therapeutics Limited in accordance with the terms of our engagement letter dated 7 Novemeber 2023Our work has been undertaken solely to prepare for your approval the financial statements of Ateda Therapeutics Limited and state those matters that we have agreed to state to the director of Ateda Therapeutics Limited in this report in accordance with ICAEW Technical Release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Ateda Therapeutics Limited and its director for our work or for this report. 

It is your duty to ensure that Ateda Therapeutics Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Ateda Therapeutics Limited. You consider that Ateda Therapeutics Limited is exempt from the statutory audit requirement for the period.

We have not been instructed to carry out an audit or review of the financial statements of Ateda Therapeutics Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

  



Kreston Reeves LLP
 
Chartered Accountants
  
Canterbury
1 May 2025
Page 1

 
Ateda Therapeutics Limited
Registered number: 15169544

Balance Sheet
As at 30 September 2024

2024
Note
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
112,521

Cash at bank and in hand
  
405,678

  
518,199

Creditors: amounts falling due within one year
 5 
(175,888)

Net current assets
  
 
 
342,311

Total assets less current liabilities
  
342,311

  

Net assets
  
342,311


Capital and reserves
  

Called up share capital 
 6 
85

Share premium account
 7 
85,290

Profit and loss account
 7 
256,936

  
342,311


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 1 May 2025.




Dr G Mariggi
Director

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
Ateda Therapeutics Limited
 

 
Notes to the Financial Statements
For the Period Ended 30 September 2024

1.


General information

Ateda Therapeutics Limited is a private company limited by shares and is incorporated in England with registration number 15169544. The registered office address of the company is Kreston Reeves, Innovation House, Ramsgate Road, Sandwich, Kent, CT13 9FF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
2.4

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 3

 
Ateda Therapeutics Limited
 

 
Notes to the Financial Statements
For the Period Ended 30 September 2024

2.Accounting policies (continued)

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the period was 1.


4.


Debtors

2024
£


Trade debtors
112,156

Prepayments and accrued income
365

112,521



5.


Creditors: Amounts falling due within one year

2024
£

Trade creditors
4,467

Corporation tax
85,645

Other taxation and social security
84,276

Accruals and deferred income
1,500

175,888


Page 4

 
Ateda Therapeutics Limited
 

 
Notes to the Financial Statements
For the Period Ended 30 September 2024

6.


Share capital

2024
£
Allotted, called up and fully paid


530,863 A Ordinary Shares shares of €0.0001- each
45
10,000 A Preference Shares shares of €0.0001- each
1
449,137 B Ordinary Shares shares of €0.0001- each
38
10,000 B Preference Shares shares of €0.0001- each
1

85





7.


Reserves

Share premium account

This reserve records the amount above the nominal value received for shares issued by the company. Share premium may only be utilised to write-off any expenses incurred or commissions paid on the issue of those shares, or to pay up new shares to be allotted to members as fully paid bonus shares.

Profit and loss account

This reserve comprises all current and prior period retained profits and losses after deducting any distributions made to the company's shareholders.


8.


Controlling party

The company is a 54.26% subsidiary of Index Ventures Life VI (Jersey), LP, a limited partnership registered in Jersey. The registered office of Index Ventures Life VI (Jersey), LP is 44 Esplanade, St. Helier, JE4 9WG, Jersey.
Index Ventures Life VI (Jersey), LP meets the definition of an Investment Entity in accordance with IFRS 10 and is not required to consolidate its investments, of which the company is an investment.


Page 5